The lawsuit, captioned Robbins v. Grail, Inc., centers on the performance of the company’s Galleri test. According to the complaint, executives allegedly projected false confidence regarding the NHS-Galleri trial, specifically the probability of achieving a statistically significant reduction in late-stage cancers. The filing claims management ignored internal data suggesting that the study's timeframe was insufficient to reach its primary endpoint.

On February 19, 2026, the company confirmed that the trial failed to demonstrate the expected reduction in Stage III-IV cancers, citing a need for longer follow-up periods. Following this disclosure, GRAIL stock plummeted by more than 50%. The law firm Robbins Geller Rudman & Dowd LLP is now seeking a lead plaintiff to represent the class. Investors seeking to participate in the litigation must submit their information to the firm to be considered for the role of lead plaintiff by the court.